ARTICLE | Company News
EngMab, Celgene deal
October 10, 2016 7:00 AM UTC
Celgene acquired EngMab for $600 million. Celgene said the acquisition will help it pursue tumor necrosis factor receptor superfamily member 17 ( BCMA; TNFRSF17; CD269) as a target to treat multipl...